Akoya Biosciences Inc [AKYA] stock is trading at $3.03, up 13.91%. An important factor to consider is whether the stock is rising or falling in short-term value. The AKYA shares have gain 24.69% over the last week, with a monthly amount glided 35.27%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Akoya Biosciences Inc [NASDAQ: AKYA] stock has seen the most recent analyst activity on November 15, 2024, when Craig Hallum downgraded its rating to a Hold and also revised its price target to $5 from $7. Previously, Morgan Stanley downgraded its rating to Equal-Weight on August 06, 2024. On August 06, 2024, downgrade downgraded it’s rating to Neutral. BTIG Research downgraded its rating to a Neutral. Craig Hallum initiated its recommendation with a Buy and recommended $7.50 as its price target on June 21, 2024.
Akoya Biosciences Inc [AKYA] stock has fluctuated between $1.88 and $6.31 over the past year. Currently, Wall Street analysts expect the stock to reach $3.5 within the next 12 months. Akoya Biosciences Inc [NASDAQ: AKYA] shares were valued at $3.03 at the most recent close of the market. An investor can expect a potential return of 15.51% based on the average AKYA price forecast.
Analyzing the AKYA fundamentals
Akoya Biosciences Inc [NASDAQ:AKYA] reported sales of 86.81M for the trailing twelve months, which represents a drop of -25.39%. Gross Profit Margin for this corporation currently stands at 0.56% with Operating Profit Margin at -0.52%, Pretax Profit Margin comes in at -0.67%, and Net Profit Margin reading is -0.67%. To continue investigating profitability, this company’s Return on Assets is posted at -0.45, Equity is -1.89 and Total Capital is -0.44. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 5.57.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.68 points at the first support level, and at 2.33 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.40, and for the 2nd resistance point, it is at 3.77.
Ratios To Look Out For
For context, Akoya Biosciences Inc’s Current Ratio is 2.75. On the other hand, the Quick Ratio is 1.85, and the Cash Ratio is 0.45. Considering the valuation of this stock, the price to sales ratio is 1.73, the price to book ratio is 11.01.
Transactions by insiders
Recent insider trading involved McKelligon Brian, President and CEO, that happened on Jun 11 ’24 when 7500.0 shares were sold. President and CEO, McKelligon Brian completed a deal on Jun 06 ’24 to sell 7500.0 shares. Meanwhile, President and CEO McKelligon Brian sold 7500.0 shares on Mar 20 ’24.
